File

Streamline Your Construction Lien Management with Bectran and NCS Credit Integration

Retrieved on: 
Thursday, March 28, 2024
Failure, Partnership, Risk, UCC, File, Collection, NCS, IDS, Risk management

CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Bectran, Inc., the industry leader in credit, collections, and accounts receivable management technology has announced a new collaboration with NCS Credit , a renowned provider of Mechanic’s Lien, UCC, and collections solutions.

Key Points: 
  • CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Bectran, Inc., the industry leader in credit, collections, and accounts receivable management technology has announced a new collaboration with NCS Credit , a renowned provider of Mechanic’s Lien, UCC, and collections solutions.
  • This partnership unveils an innovative Mechanic’s Lien integration solution tailored specifically for construction professionals, providing users with a streamlined approach to safeguard their projects and efficiently submit notice and Mechanic’s Lien information.
  • NCS continually explores technology partnerships that align with our clients’ goals to improve efficiency and effectiveness across both credit and collection departments.” – Adrian Segedy, Director of Sales, NCS Credit
    Our integration with NCS Credit will allow Bectran’s customers to submit preliminary lien notices to NCS directly through our platform, eliminating redundancy and duplicate entry.
  • Bectran’s integration with NCS Credit simplifies the preliminary notice and Mechanic’s Lien management process, improving oversight of the construction payment chain.

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Research, HNC, Symantec Endpoint Protection, Head, Type, Manganese, Chronic kidney disease, Incidence, ASN, CKD, New Drug Application, LAPC, Patient, Layoff, CRL, NDA, Cancer, Galera, Workforce, Pancreatic cancer, Clinical trial, Cisplatin, Society, Therapy, GRECO, File, Food, SOM, FDA, PDUFA, Pharmaceutical industry

We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.

Key Points: 
  • We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.
  • The Prescription Drug User Fee Act (PDUFA) target date assigned by the FDA for the NDA was August 9, 2023.
  • Research and development expenses were $3.2 million in the fourth quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $2.0 million in the fourth quarter of 2023, compared to $5.0 million for the same period in 2022.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, March 28, 2024
Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Plaque, Prospectus, Complaint, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points: 
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • As of the time the Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

Sequana Medical announces 2023 Full Year Results and 2024 Outlook

Retrieved on: 
Thursday, March 28, 2024
Cardiorenal syndrome, Cirrhosis, Partner, Congestion, American Medical Association, Ascites, DSR, Brussels Stock Exchange, Liver disease, RED, Patient, Peritoneal dialysis, 2.0, Mouse, Sheep, Cancer, Heart, Heart failure, PMA, US FDA, Safety, File, CPT9, Overload, Catheter, ISO, THT, FDA, Animal, Pharmaceutical industry

Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.

Key Points: 
  • Ian Crosbie, Chief Executive Officer of Sequana Medical, commented: “Securing PMA approval is a major value inflection point and the team is navigating through the approval process.
  • Furthermore, the alfapump can benefit from attractive pricing and leverage its FDA breakthrough device designation to enhance its reimbursement position.
  • Following this equity placement, the €3.0 million convertible loan agreement entered in February 2024 by Partners in Equity and Rosetta Capital will be mandatorily converted into new shares.
  • A day-100 meeting is scheduled with the FDA on April 9th 2024.

PiCockpit: Innovative Web Solution for Managing Multiple Raspberry Pis

Retrieved on: 
Wednesday, March 27, 2024
Web browser, Schedule, Partnership, Terminal, PuTTY, Software, Linux, Raspberry Pi, WebRTC, File, Gesellschaft mit beschränkter Haftung

The PiCockpit Terminal App offers a seamless web-based terminal interface, eliminating the need for complex setup or additional software like PuTTY.

Key Points: 
  • The PiCockpit Terminal App offers a seamless web-based terminal interface, eliminating the need for complex setup or additional software like PuTTY.
  • Leveraging WebRTC technology, it ensures a secure, encrypted connection for managing all Raspberry Pi devices from any location.
  • The File Editor App, enhanced with RaspiGPT technology powered by OpenAI's GPT-4, simplifies file and directory management on Raspberry Pis.
  • With Two Factor Authentication, PiCockpit ensures secure access to user accounts and their Raspberry Pis.

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA

Retrieved on: 
Wednesday, March 27, 2024
Diagnosis, NMPA, Patient, Ageing, NDA, Breakthrough, CDE, Duchenne muscular dystrophy, Therapy, Vamorolone, Safety, File, DMD, Neuromuscular disease, Pharmaceutical industry

Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted by Sperogenix Therapeutics, Santhera's specialized rare disease partner for China.

Key Points: 
  • Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted by Sperogenix Therapeutics, Santhera's specialized rare disease partner for China.
  • The Center for Drug Evaluation (CDE) of the Chinese drug authority NMPA accepted the filing and granted priority review for vamorolone in DMD for patients aged 4 years and older which could, subject to a positive outcome, lead to approval by Q1 2025.
  • Duchenne muscular dystrophy is a rare neuromuscular disease affecting about 70,000 patients in China.
  • The submission is further supported by a study which investigated the pharmacokinetic parameters of vamorolone in healthy adult Chinese volunteers.

VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Retrieved on: 
Tuesday, April 9, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, 3rd Floor, Disease, Vaccine, Sale, Security (finance), Prospectus, File, VBI, Regulation D

In a concurrent private placement, VBI will issue unregistered warrants to purchase up to 2,272,728 common shares.

Key Points: 
  • In a concurrent private placement, VBI will issue unregistered warrants to purchase up to 2,272,728 common shares.
  • The gross proceeds to VBI from this offering are expected to be approximately $2 million, before deducting the placement agent’s fees and other offering expenses.
  • The offering of the securities in the registered direct offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of an effective registration statement.
  • A prospectus supplement and accompanying prospectus relating to the registered direct offering will be filed with the SEC.

DFIN Completes Its First Test Filing Ahead of Tailored Shareholder Reports Deadline

Retrieved on: 
Tuesday, April 9, 2024
TSR, Risk, DFIN, Donnelley Financial Solutions, File, Security (finance)

CHICAGO, April 9, 2024 /PRNewswire/ -- Donnelley Financial Solutions (NYSE: DFIN), a leading provider of risk and compliance solutions, today announced it has met a critical milestone in advance of the July 24 compliance deadline for the Tailored Shareholder Reports (TSR) rule.

Key Points: 
  • CHICAGO, April 9, 2024 /PRNewswire/ -- Donnelley Financial Solutions (NYSE: DFIN), a leading provider of risk and compliance solutions, today announced it has met a critical milestone in advance of the July 24 compliance deadline for the Tailored Shareholder Reports (TSR) rule.
  • The SEC adopted the TSR regulation as part of its continued effort to modernize and simplify shareholder communications.
  • It requires significant changes to both the content and the presentation of information to create standardized and visually engaging shareholder reports.
  • "This successful iXBRL tagged N-CSR/TSR test filing demonstrates our leadership in the industry and commitment to deliver a streamlined solution for a complex regulation.

47% of TAX FILERS DELAY FILING RETURNS

Retrieved on: 
Monday, April 8, 2024
Millennials, IRS, Tax, Paralysis, Tax Day, Ageing, Research, DIY, Assist, Age, File, TaxAct, Procrastination, Emotion, Online shopping

DALLAS, April 8, 2024 /PRNewswire/ -- TaxAct® today released new research that showcases the stress American tax filers feel as Tax Day looms. The State of Taxpayer Stress in America highlights how procrastination gets in the way of starting the process of filing a return—even when people expect to get a tax refund. Why delay filing and retrieval of that sweet refund? Stress.

Key Points: 
  • DALLAS, April 8, 2024 /PRNewswire/ -- TaxAct® today released new research that showcases the stress American tax filers feel as Tax Day looms.
  • The survey found 47% of tax filers delay the task.
  • When they finally do get around to filing, 61% of tax filers take at least one break from the process before returning to file and taking their victory lap.
  • For Millennials, a desire to delay filing might stem from reaching new life stages, such as marriage or homeownership, that can complicate their tax profile.

Crown Castle Issues Open Letter to Shareholders

Retrieved on: 
Monday, March 25, 2024
Sprint, BofA Securities, Tax, Verizon Communications, Letter, Ted, File, Face, Exercise, CFO, Name, Shirin David, Shareholder, Strategic planning, Integration, Sale, CCI, Motion, Security (finance), Senior, Outline, Morgan Stanley, REIT, Person, T-Mobile, Boots (company), Interim, Telecommunications, American Tower, Family, CTIA, Consultant, Annual general meeting

HOUSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Crown Castle Inc. (NYSE: CCI) (“Crown Castle” or the “Company”) today filed its preliminary proxy materials with the Securities and Exchange Commission (“SEC”) in connection with its 2024 Annual Meeting of Stockholders to be held on May 22, 2024.

Key Points: 
  • The Crown Castle Board of Directors unanimously recommends shareholders use the WHITE proxy card to vote FOR only the twelve nominees proposed by our Board of Directors.
  • The Board values feedback from all of its shareholders, and as we advance these initiatives, we are committed to acting in our shareholders’ best interests by positioning Crown Castle for long-term success and value creation.
  • Crown Castle today is very different than it was 22 years ago when Mr. Miller was last at the Company.
  • Boots Capital’s proposal does not create any actual tax “savings” to Crown Castle, because Crown Castle is a REIT and does not pay taxes as long as it pays distributions to shareholders equal to its taxable income each year.